HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Defective postreperfusion metabolic recovery directly associates with incident delayed graft function.

Abstract
Delayed graft function (DGF) following kidney transplantation affects long-term graft function and survival and is considered a manifestation of ischemia reperfusion injury. Preclinical studies characterize metabolic defects resulting from mitochondrial damage as primary driver of ischemia reperfusion injury. In a comprehensive approach that included sequential establishment of postreperfusion arteriovenous concentration differences over the human graft, metabolomic and genomic analysis in tissue biopsies taken before and after reperfusion, we tested whether the preclinical observations translate to the context of clinical DGF. This report is based on sequential studies of 66 eligible patients of which 22 experienced DGF. Grafts with no DGF immediately recovered aerobic respiration as indicated by prompt cessation of lactate release following reperfusion. In contrast, grafts with DGF failed to recover aerobic respiration and showed persistent adenosine triphosphate catabolism indicated by a significant persistently low post reperfusion tissue glucose-lactate ratio and continued significant post-reperfusion lactate and hypoxanthine release (net arteriovenous difference for lactate and hypoxanthine at 30 minutes). The metabolic data for the group with DGF point to a persistent post reperfusion mitochondrial defect, confirmed by functional (respirometry) and morphological analyses. The archetypical mitochondrial stabilizing peptide SS-31 significantly preserved mitochondrial function in human kidney biopsies following simulated ischemia reperfusion. Thus, development of DGF is preceded by a profound post-reperfusion metabolic deficit resulting from severe mitochondrial damage. Strategies aimed at preventing DGF should be focused on safeguarding a minimally required post-reperfusion metabolic competence.
AuthorsLeonie G M Wijermars, Alexander F Schaapherder, Dorottya K de Vries, Lars Verschuren, Rob C I Wüst, Sarantos Kostidis, Oleg A Mayboroda, Frans Prins, Jan Ringers, Jörgen Bierau, Jaap A Bakker, Teake Kooistra, Jan H N Lindeman
JournalKidney international (Kidney Int) Vol. 90 Issue 1 Pg. 181-91 (07 2016) ISSN: 1523-1755 [Electronic] United States
PMID27188504 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2016 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.
Chemical References
  • Oligopeptides
  • arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide
Topics
  • Allografts (metabolism, pathology)
  • Biopsy
  • Cohort Studies
  • Delayed Graft Function (epidemiology, etiology, metabolism, pathology)
  • Female
  • Graft Survival
  • Humans
  • Incidence
  • Kidney (drug effects, metabolism, pathology)
  • Kidney Transplantation (adverse effects)
  • Male
  • Middle Aged
  • Mitochondria (drug effects, metabolism, pathology)
  • Oligopeptides (therapeutic use)
  • Reperfusion Injury (complications, drug therapy, metabolism, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: